Welcome to the e-CCO Library!

P711 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to adalimumab in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Guardiola Capón1, K. SERRA1, L. Rodríguez-Alonso1, E. Santacana2, A. Padró3, N. Padullés2, A. Ruiz-Cerulla1, C. Arajol1, B. Camps1, G. Surís1, J. Orobitg1, F. Rodríguez-Moranta1

Created: Thursday, 30 January 2020, 10:12 AM
P711: A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of response
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Restellini1,2*, T. Bessissow1, C. Lemieux1, C.-Y. Chao1,3, G. Wild1, E. Seidman1, A. Bitton1, P.L. Lakatos1,4, W. Afif1

Created: Thursday, 21 February 2019, 9:14 AM
P711: Decreased steroid exposure and disease-related hospitalizations in patients with newly diagnosed inflammatory bowel disease in the era of newer biologic agents – A multi-centre experience in Singapore.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yeo, G.D.D.(1)*;Qui, M.(2);Pak, W.C.W.(1);Tan, C.K.(3);Tay, S.W.(1);Lim, C.T.T.(1);Tan, T.K.M.(1);Ong, W.C.(4);Lim, T.G.(4);Ng, Y.T.V.(4);Wong, S.Y.A.(4);Salazar, E.(1);
Created: Friday, 14 July 2023, 11:12 AM
P711: Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment
Year: 2022
Source: ECCO'22
Authors: VerburgtMD, C.(1);Dunn, K.A.(2);Bielawski, J.P.(3);Otley, A.R.(4);Heyman, M.B.(5);Sunseri, W.(6);Shouval, D.(7);Levine, A.(8);de Meij, T.(1);Hyams, J.S.(9);Denson, L.A.(10);Kugathasan, S.(11);Benninga, M.A.(1);de Jonge, W.J.(12);Van Limbergen, J.E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P711: The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Amiot*1, M. Serrero2, L. Peyrin-Biroulet3, J. Filippi4, B. Pariente5, X. Roblin6, A. Buisson7, C. Stefanescu8, C. Trang-Poisson9, R. Altwegg10, P. Marteau11, T. Vaysse12, A. Bourrier13, S. Nancey14, D. Laharie15, M. Allez16, G. Savoye17, J. Moreau18, L. Vuitton19, S. Viennot20, A. Aubourg21, A-L. Pelletier22, G. Bouguen23, V. Abitbol24, M. Fumery25, C. Gagniere1, Y. Bouhnik8

Created: Friday, 22 February 2019, 9:41 AM
P711: Vegetarian or gluten-free diet in patients with IBD – associated with lower psychological well-being and quality of life but no indication of beneficial effects on course of disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Schreiner P.*1, Rossel J.-B.2, Zeitz J.1, Misselwitz B.1, Scharl S.1, Scharl M.1, Frei P.3, Vavricka S.4, Pittet V.2, Rogler G.1, Biedermann L.1

Created: Wednesday, 20 February 2019, 10:36 AM
P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Li1, F. Yang1, C. Marano1, H. Zhang2, W.J. Sandborn3, B.E. Sands4, B.G. Feagan5, D.T. Rubin6, L. Peyrin-Biroulet7, J.R. Friendman1, G. De Hertogh8

Created: Thursday, 30 January 2020, 10:12 AM
P712: Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modelling
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Doshi*, E. Krishnan, H. Wang, N. Zhang, V. Chow

Created: Thursday, 21 February 2019, 9:14 AM
P712: Fungal microbiota composition in Inflammatory Bowel Disease patients in a Norwegian cohort: characterization of disease phenotypes and correlation with clinical activity and disease course.
Year: 2022
Source: ECCO'22
Authors: Catalàn-Serrax, I.(1,2,3);Thorsvik, S.(3,4);Beisvag, V.(2);Bruland, T.(2);Underhill, D.(3,5,6);Sandvik, A.K.(2,3,4);Van Beelen Granlund, A.(2,3,4);
Created: Friday, 11 February 2022, 3:56 PM
P712: Real-World Efficacy And Safety Of Ustekinumab And Adalimumab In Patients With Crohn's Disease: Propensity Matched Analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Shin, Y.(1);Hong, S.N.(1)*;Kim, E.R.(1);Chang, D.K.(1);Kim, Y.H.(1);
Created: Friday, 14 July 2023, 11:12 AM
P712: Risk factors for the development of fistulae and stenoses in Crohn's disease patients in the Swiss IBD cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zeitz J.*1, Fournier N.2, Labenz C.3, Biedermann L.4, Frei P.5, Misselwitz B.4, Scharl S.4, Vavricka S.4,6, Sulz M.7, Fried M.8, Rogler G.4, Scharl M.4

Created: Wednesday, 20 February 2019, 10:36 AM
P712: Tofacitinib efficacy in patients with moderate to severe ulcerative colitis: Subgroup analyses of OCTAVE Induction 1 and 2 and OCTAVE Sustain by 5-aminosalicylates use
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Hanauer1, D. T. Rubin2, P. Gionchetti3, C. Su4, D. A. Woodworth4, D. Quirk4, L. Salese4, W. Wang4, A. Marren4, N. Lawendy4, R. Panaccione*5

Created: Friday, 22 February 2019, 9:41 AM
P713 Effects of vedolizumab on health-related quality of life, work productivity and patient concerns in patients with ulcerative colitis and Crohn’s disease in the UK and Ireland: OCTAVO cohort 2
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Parkes1, A. Akbar2, I. Beales3, M. Buckley4, T. Creed5, S. Din6, A. Fraser5, N. Plevris7, S. Meadowcroft8, G. Owen9, N. Heggs8, OCTAVO

Created: Thursday, 30 January 2020, 10:12 AM
P713: Gut microbiota alterations after bowel preparation amongst inflammatory bowel disease patients
Year: 2022
Source: ECCO'22
Authors: Rutka, M.(1);Szántó, K.(1);Bacsur, P.(1);Resál, T.(1);Jójárt, B.(2);Bálint, A.(1);Ari, E.(3);Kintses, B.(4);Fehér, T.(4);Asbóth, A.(5);Pigniczki, D.(1);Bor, R.(1);Fábián, A.(1);Farkas, K.(1);Maléth, J.(2);Szepes, Z.(1);Molnár, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P713: Home-based vedolizumab infusions: A suitable alternative to routine hospital infusions
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Peek-Kuijt1*, J. Nieuwstraten1, L. van Ginkel2, J. Maljaars1, A. van der Meulen- de Jong1

Created: Thursday, 21 February 2019, 9:14 AM
P713: Long-term efficacy of endoscopic balloon dilatation using single-balloon enteroscopy in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Takahashi*1, S. Bamba2, Y. Morita1, A. Nishida1, M. Sasaki2, T. Tsujikawa3, A. Andoh1

Created: Friday, 22 February 2019, 9:41 AM
P713: Possible explanations of the marked differences in the incidence of microscopic colitis between Denmark and Sweden
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Davidson S.*1, Munck L.2, Vigren L.3, Engel P.4, Sjöberg K.3

Created: Wednesday, 20 February 2019, 10:36 AM
P713: Proactive therapeutic infliximab monitoring during induction phase in inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gonzalez Vivo, M.(1,2)*;Carballo Martinez, N.(2,3);Padulles Zamora, N.(4);Colominas Gonzalez, E.(2,3);Murciano Gonzalo, F.(1);Abril Rodriguez, L.(1);Marquez-Mosquera, L.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P714 Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. ERIKSSON1, S. Rundquist1, V. Lykiardopoulos2, R. Udumyan3, P. Karlén4, O. Grip5, C. Söderman6, S. Almer7, E. Hertervig8, J. Gunnarsson9, C. Malmgren10, J. Delin11, H. Strid12, M. Sjöberg13, D. Öberg14, D. Bergemalm1, H. Hjortswang2, J. Halfvarson1

Created: Thursday, 30 January 2020, 10:12 AM
P714: Comparison of intestinal microbiota profiles of faecal samples, rectal swabs and mucosal biopsies in patients with Inflammatory Bowel Disease. A multicentre, observational study.
Year: 2022
Source: ECCO'22
Authors: Van Rossen, T.(1);van den Hoek, K.(2);Budding, A.(3);van Bodegraven, A.(4);
Created: Friday, 11 February 2022, 3:56 PM